L3 breast cancer: 
	- primary prevention:
		- BRCA1/2: mastectomy + oophorectomy
		- tx: tamoxifen (SERM) + aromatase inhibitor
		- prevent BC: "Think Aromatase": T + AI

	- tx:
		- surgery:
			- mastetomy vs lumpectomy
			- sentinel node vs axillary node biopsy
		- radiation:
			- if lumpectomy
			- if mastectomy + large tumor or node involvement
		
		- systemic:
			- everything: chemotherapy:
				- regimen:
					- doxorubicin
					- cyclophosphamide
					- taxanes
					- CDT
			
			- anti-HER2+: trastuzumab/pertuzumab x 1yr
			- HR+/PR+: tamoxifen or aromatase inhibitor x 5-10 years

		- post-treatment:
			- regular mammograms, physicals
			- no scans/biomarkers if asymptomatic
			- BRAC1/2: give PARPi

	- metastatic tx:
		- ER+/PR+:
			- aromatase inhibitors
			- CDK 4/6 inhibitors
		- HER2+:
			- chemo
			- anti-HER2: trastuzumab/pertuzumab
			- ADC: T-Dxd
		- triple negative: chemo + anti-PD1
		- general metastatic: sacituzimab govitecan
		- supportive: bisphosphonates / denosumab
			 


L7 lung cancer:
	- NSCLC:
		- tx:
			- chemo:
				- Tobacco Promotes Growth -> TPG -> Taxanes + Platinums + Gemcitabine
			- anti-PD1
			- EGFR inhibitors: osimertinib, erlotinib
			- ALK + RET inhibitor: alectinib
			- BRAF V600E inhibitors: dabrafenib + trametinib
			- KRAS: sotorasib
			- HER2 mutation: TdX-T

	- SCLC:
		- tx:
			- chemo: platinum + etoposide
				- small cell -> small PE -> Platinum + Etoposide
			- radiation:
				- concurrent w/ chemo
				- prophylactic cranial irradiation (PCI)

L10 colorectal cancer:
	- tx:
		- chemo:
			- colon cancer: FOLFOX -> Fluorouracil + Oxaliplatin
			- rectal cancer: radiation + capecitabine -> adjuvant oxaliplatin
	- metastatic tx: chemo + targetted
		- chemo: FOLFOX
		- targeted:
			- anti-VEGF: bevacizumab
			- anti-EFGR: cetuximab - only in RAS WT
		- MSI high: anti-PD1


L12: prostate cancer
	- tx:
		- localized:
			- surgery (prostatectomy):
				- risks:
					- ED - 43% at 2 years
					- incontinence: 15% at 2 years
			- radiation:
				- risks similar to surgery
				- external beam:
					- low risk for incontinence
				- brachytherapy: radioactive seeds
			- active surveillance:
				- less risks, but similar to surgery
				- PSA every 3 mo
		
		- metastatic:
			- hormonal therapy:
				- androgen deprivation therapy (ADT):
					- goal: testosterone < 50 ng/ml
					- GnRH agonists: goserelin, leuprolide
					- antiandrogen: bicalutamide
						- initial GnRH androgen flare
				- orchiectomy:
					- quick, cost effective

			- castrate resistant prostate cancer (CRPC):
				- prostate cancer -> CRPC after ~2 years of ADT
				- metastatic lethal form
				- tx:
					- chemo: docetaxel
					- hormonal:
						- abitarone + prednisone
						- enzulatamide
					- immune: car-T - sipuleucel-T
					- radium 223: targets bone mets
				
				- supportive care (for bone mets):
					- zoledronic acid (bisphosphonates)
						- inhibits Ca release from tumors
					- denosumab:


L15 oncology rounds I:
	- bladder cancer:
		- tx:
			- bacillus calmette-guerin (BCG)
			- mitomycin
	- melanoma:
		- anti-PD1
		- BRAF V600E: BRAFi + MEKi
	- head + neck: no tx given
	- gastric: amoxicillin for H. pylori


L16 oncology rounds II:
	- ovarian cancer:
		- tx:
			- chemo: PT - platinums + taxanes: carboplatin + paclitaxel
	- liver cancer:
		- tx: resection/transplant

	- pancreatic cancer:
		- tx:
			- surgery
			- chemo: gemcitabine + 5FU

	- renal cell carinoma:
		- tx:
			- sunitinib/pazopanib
			- anti-PD1
			- anti-VEGF: bevacizumab


L17 oncology rounds III:
	- ewing's sarcoma:
		- tx:
			- COD EIght:
				- COD: Cyclophosphamide + Ovincristine + Doxorubicin
				- EIght: etoposide + ifosfamide

	- gastrointestinal stromal tumor (GIST):
		- tx:
			- surgery
			- targeted: imatinib for cKIT

	- testicular cancer:
		- tx:
			- surgery: orchiectomy
			- chemo: EBC: Expell Ball Cancer - Etoposide + Bleomycin + Cisplatin